Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy. Therapy with anti-tumor necrosis factor (TNF)-α agents represents the first therapeutic choice for moderate and severe forms; however, PsA patients can experience anti-TNFα failure, lack of efficacy, or adverse events. Several evidences exist on the effectiveness of switching among different TNFα inhibitors, and we reviewed the published data on the effectiveness of anti-TNFα first-, second- and third-line. Most of the studies report that the main reason for switching to a second anti-TNFα agent is represented by lack of efficacy (primary or secondary) and, more rarely, adverse events. Switchers receiving their second anti-TNFα agent have considerably poorer responses compared with non-switchers. Survival of anti-TNFα treatment appears to be superior in PsA patients when compared with rheumatoid arthritis patients. Switching from anti-TNF agents to ustekinumab or secukinumab or apremilast can represent a valid alternative therapeutic strategy.

Costa, L., Perricone, C., Chimenti, M.s., Del Puente, A., Caso, P., Peluso, R., et al. (2017). Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence. DRUGS IN R&D, 17(4), 509-522 [10.1007/s40268-017-0215-7].

Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence

Costa L.;Chimenti M. S.;
2017-01-01

Abstract

Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy. Therapy with anti-tumor necrosis factor (TNF)-α agents represents the first therapeutic choice for moderate and severe forms; however, PsA patients can experience anti-TNFα failure, lack of efficacy, or adverse events. Several evidences exist on the effectiveness of switching among different TNFα inhibitors, and we reviewed the published data on the effectiveness of anti-TNFα first-, second- and third-line. Most of the studies report that the main reason for switching to a second anti-TNFα agent is represented by lack of efficacy (primary or secondary) and, more rarely, adverse events. Switchers receiving their second anti-TNFα agent have considerably poorer responses compared with non-switchers. Survival of anti-TNFα treatment appears to be superior in PsA patients when compared with rheumatoid arthritis patients. Switching from anti-TNF agents to ustekinumab or secukinumab or apremilast can represent a valid alternative therapeutic strategy.
2017
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
English
Costa, L., Perricone, C., Chimenti, M.s., Del Puente, A., Caso, P., Peluso, R., et al. (2017). Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence. DRUGS IN R&D, 17(4), 509-522 [10.1007/s40268-017-0215-7].
Costa, L; Perricone, C; Chimenti, Ms; Del Puente, A; Caso, P; Peluso, R; Bottiglieri, P; Scarpa, R; Caso, F
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/191654
Citazioni
  • ???jsp.display-item.citation.pmc??? 22
  • Scopus 65
  • ???jsp.display-item.citation.isi??? 64
social impact